cFluor® B515 Anti-Human HLA-DR (L243)
The L243 monoclonal antibody binds to the human HLA-DR antigen, a 36-kDa alpha heavy chain and a 27-kDa beta light chain heterodimeric cell surface glycoprotein in transmembrane major histocompatibility complex 2 (MHC II) family (1)(2). HLA-DR, also known as human leukocyte antigen DR isotype, is present on the surface of antigen-presenting cells, including B cells, dendritic cells, macrophages, monocytes and activate T cells. MHC class II regulates the immune system by playing a critical role in binding and presenting antigen-derived peptides to peptide-MHC II-specific CD4 T cells (3). The antibody was conjugated to a fluorophore and puriﬁed by afﬁnity chromatography.
Reactivity: Human, African Green, Baboon, Chimpanzee, Cynomolgus, Dog (Canine), Marmoset, Rhesus, Squirrel Monkey, Tamarin
Format: cFluor® B5151
Isotype: Mouse IgG2a, κ
Tested Dilution: 5 μL / test
Application: Flow Cytometry
Storage: 2-8°C and protected from Light. Do not freeze
Formulation: Phosphate-buffered saline, pH 7.2, containing 0.09% sodium azide and 0.2% BSA (BSA Country of Origin USA).
- Korman, A J et al. 1982. Proc Natl Acad Sci U S A. 79(19):6013-6017
- Shackelford DA, et al. 1982. Immunol Rev. 66:133-87
- Walseng E, et al. 2008. J Biol Chem. 23;283(21):14717-27
This product is intended for in vitro diagnostic use to identify human cells expressing HLA-DR antigen molecules in countries where the regulatory approval has been obtained from the local regulatory authorities.
1cFluor® B515 is equivalent to CF®488A manufactured and provided by Biotium, Inc. under an Agreement between Biotium and Cytek (LICENSEE). The manufacture, use, sale, offer for sale, or import of the product is covered by one or more of the patents or pending applications owned or licensed by Biotium. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser’s own internal research. No right under any other patent claim, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser's activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel.